

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to the accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 01011)**

## **INSIDE INFORMATION**

### **TRANSFER OF SHARES BY THE CONTROLLING SHAREHOLDER**

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company has been notified by Golden Base Investment Limited (“**Golden Base**”) that on 6 November 2019, Golden Base transferred 200,000,000 shares of the Company (representing approximately 10.5% of the total issued share capital of the Company as at the date of this announcement) (the “**Transfer**”) to Mr. Jeong Chong Mang (“**Mr. Jeong**”) at a consideration of HK\$0.41 per share.

Golden Base is a company held as to 50% and 50% by Mr. Ng Tit (“**Mr. Ng**”), an executive Director, the chairman of the Board and the chief executive officer of the Company, and Ms. Chin Yu (“**Ms. Chin**”), an executive Director and the spouse of Mr. Ng, respectively. Immediately prior to the Transfer, each of Mr. Ng, Ms. Chin and Golden Base was a controlling shareholder (as defined in the Listing Rules) of the Company. Upon completion of the Transfer, each of Mr. Ng, Ms. Chin and Golden Base shall cease to be a controlling shareholder (as defined in the Listing Rules) of the Company.

The Company does not expect the Transfer to have any material adverse effect on the operations and/or business of the Group.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**China NT Pharma Group Company Limited**  
**Ng Tit**  
*Chairman*

Hong Kong, 7 November 2019

*As at the date of this announcement, the executive Directors are Mr. Ng Tit, Ms. Chin Yu, Mr. Wu Weizhong and Mr. Wang Fei; the non-executive Directors are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive Directors are Mr. Patrick Sun, Mr. Tze Shan Hailson Yu and Dr. Hong Yan.*